X4 Pharmaceuticals (XFOR) Liabilities and Shareholders Equity (2017 - 2025)

X4 Pharmaceuticals (XFOR) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $290.5 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 98.34% year-over-year to $290.5 million; the trailing twelve-month figure through Dec 2025 stood at $689.2 million (up 6.46% YoY), and the FY2025 full-year result was $290.5 million, up 98.34% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $290.5 million, up from $163.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $290.5 million in Q4 2025 and bottomed at $81.0 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $144.1 million (2021), against an average of $147.2 million.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity surged 114.02%; it then slumped 50.07% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $117.2 million in 2021, then jumped by 32.78% to $155.6 million in 2022, then decreased by 5.35% to $147.3 million in 2023, then decreased by 0.55% to $146.4 million in 2024, then surged by 98.34% to $290.5 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $290.5 million (Q4 2025), $163.6 million (Q3 2025), and $105.2 million (Q2 2025), per Business Quant data.

Peer Comparison